M
Michele Bartoletti
H指数:22
被引数:1,399
浏览量:0
个人简介
暂无内容
教育背景
暂无内容
工作经历
暂无内容
荣誉奖项
暂无内容
KELIM score: A marker of chemosensitivity in ovarian cancer
KELIM评分:卵巢癌化疗敏感性的标志物
Cancer Treatment Reviews
IF10.5
Real-world use of cefiderocol as monotherapy or combination therapy for the treatment of Gram-negative bacterial infections: the multicentre retrospective CEFI-BAC study
头孢地尔ocol在治疗革兰氏阴性菌感染中的实际应用:单药治疗或联合治疗——多中心回顾性CEFI-BAC研究
Homologous recombination repair status in advanced endometrial cancer: an exploratory biomarker analysis from the randomized, phase II MITOEND 3 trial
高级别子宫内膜癌中的同源重组修复状态:来自随机、II期MITOEND 3试验的探索性生物标志物分析
ESMO Open
IF8.3
Exceptional Response to Trastuzumab Deruxtecan (T-DXd) in HER2-Positive Metastatic Endometrial Cancer
曲妥珠单抗德鲁替康(T-DXd)在HER2阳性转移性子宫内膜癌中的显著疗效
How to manage patients receiving long-term suppressive antibiotic treatment for infective endocarditis: the role of [18F]-FDG-PET/CT imaging - An international multidisciplinary survey
如何管理接受长期抑菌抗生素治疗的心脏瓣膜感染患者:[18F]-FDG-PET/CT成像的作用——一项国际多学科调查
Risk Factors for Persisting SARS-CoV-2 Infection in Patients with B-Cell Malignancies in the Omicron Era: A Multicenter Cohort Study
奥密克戎时代B细胞恶性肿瘤患者持续性SARS-CoV-2感染的危险因素:一项多中心队列研究
A randomized, phase III study of sacituzumab govitecan versus treatment of physician’s choice in patients with endometrial cancer after platinum-based chemotherapy and immunotherapy: the ASCENT-GYN-01 study (GOG-3104/ENGOT-en26/APGOT-EN2)
一项关于sacituzumab govitecan与医生选择治疗方案在经过铂类化疗和免疫治疗后的子宫内膜癌患者中的随机、III期研究:ASCENT-GYN-01研究(GOG-3104/ENGOT-en26/APGOT-EN2)。
Role of remdesivir for the treatment of COVID-19 in patients with hematologic malignancy—A narrative review and expert opinion
瑞德西韦在血液系统恶性肿瘤患者中治疗COVID-19的作用——一篇叙述性综述和专家意见
First-line combination therapy with fifth generation cephalosporins plus daptomycin compared to other-antimicrobial-regimens for methicillin-resistant Staphylococcus aureus bacteraemia: a multicenter retrospective cohort study
与其它抗菌药物方案相比,使用第五代头孢菌素联合达托霉素作为一线联合疗法治疗耐甲氧西林金黄色葡萄球菌菌血症的多中心回顾性队列研究
Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis
将anti-PD1或抗PD-L1药物掺入基于铂的化疗,用于晚期或复发性子宫内膜癌的初步治疗。一项荟萃分析
CANCER TREATMENT REVIEWS
IF10.5

